凤尾草颗粒剂治疗良性前列腺增生症的临床疗效评价

目的 观察中药凤尾草颗粒剂治疗良性前列腺增生症（BPH）的疗效。方法 将155例BPH患者分为中药治疗组（108例）和西药对照组（47例），中药组予凤尾草颗粒剂5 g，每天2次口服，西药组予保列治每天5 mg顿服，两组均连续用药3个月。观察治疗前后国际前列腺症状评分(I PSS)、最大尿流率(MFR)、经腹B超测膀胱残余尿量、前列腺体积的变化。结果 与治疗前比较，治疗后两组患者的I PSS评分、MFR及残余尿量均明显改善(P<0.05或<0.01)，前列腺体积的改变差异无统计学意义；两组治疗后比较差异亦无统计学意义(P＞0.05)。结论 中药凤尾草颗粒剂治疗BPH具有较好的疗效，且不良反应少。

Clinical Evaluation on Fengweicao Granule in Treating Benign Prostatic Hyperplasia

OBJECTIVE:To report the effect of Fengweicao Granule (FWCCG), a Chinese herbal preparation made of herba Pteris multifidae, in treating benign prostatic hyperplasia (BPH). METHODS: One hundred and fifty-five patients were assigned to two groups, the 108 patients in the treated group were administered orally with FWCG twice a day, 5 g every time; the 47 patients in the control group were treated with Proscar 5 mg per day for 3 months. The effects were evaluated by the change of the related indexes before and after treatment, including scoring by international prostatic symptom scale (I-PSS), maximum flowing rate of urine (MFR), residue urine volume (RU) in urinary bladder determined by abdominal B-ultrasonography and volume of prostate. RESULTS: After being treated for 3 months, the I-PSS, MFR and RU improved remarkably in both groups (P <0.05 or P <0.01), but with no significant change in the volume of prostate, neither with significant difference in comparison between the two groups (P >0.05). CONCLUSION: FWCG has a good effect with less adverse reaction in treating BPH.